MX2023002818A - Oligonucleotido de cadena simple. - Google Patents

Oligonucleotido de cadena simple.

Info

Publication number
MX2023002818A
MX2023002818A MX2023002818A MX2023002818A MX2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A
Authority
MX
Mexico
Prior art keywords
nucleotide sequence
hybridize
oligonucleotide
stranded oligonucleotide
nucleotides
Prior art date
Application number
MX2023002818A
Other languages
English (en)
Inventor
Hiroyuki Nakajima
Yusuke Iriyama
Tatsuro Kanaki
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59398721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023002818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of MX2023002818A publication Critical patent/MX2023002818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un oligonucleótido de cadena simple que es capaz de controlar un gen objetivo con alta eficiencia y puede producirse fácilmente; el oligonucleótido de cadena simple es representado por la fórmula X-L-Y en donde X y Y se hibridan mediante una primera porción de la secuencia de nucleótidos y una segunda porción de la secuencia de nucleótidos; X está compuesta de 7 a 100 nucleótidos, contiene por lo menos un nucleótido modificado, y tiene una primera secuencia de nucleótidos que es capaz de hibridarse con un segundo oligonucleótido y contiene por lo menos cuatro nucleótidos contiguos reconocidos por RNasa H; Y está compuesta de 4 a 100 nucleótidos, y tiene una segunda secuencia de nucleótidos que es capaz de hibridarse con un segundo oligonucleótido y contiene por lo menos un ribonucleótido; por lo menos una de la secuencia de nucleótidos X y la secuencia de nucleótidos Y tiene una secuencia antisentido capaz de hibridarse con un ARN objetivo; L es un grupo derivado de un tercer oligonucleótido que se degrada bajo condiciones fisiológicas.
MX2023002818A 2016-01-26 2018-07-25 Oligonucleotido de cadena simple. MX2023002818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016012804 2016-01-26
JP2016158833 2016-08-12

Publications (1)

Publication Number Publication Date
MX2023002818A true MX2023002818A (es) 2023-03-17

Family

ID=59398721

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009090A MX2018009090A (es) 2016-01-26 2017-01-26 Oligonucleótido de cadena simple.
MX2023002818A MX2023002818A (es) 2016-01-26 2018-07-25 Oligonucleotido de cadena simple.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009090A MX2018009090A (es) 2016-01-26 2017-01-26 Oligonucleótido de cadena simple.

Country Status (10)

Country Link
US (2) US11530409B2 (es)
EP (1) EP3409779A4 (es)
JP (3) JP6988481B2 (es)
CN (2) CN116064544A (es)
AU (1) AU2017211461B2 (es)
BR (1) BR112018015164A2 (es)
CA (1) CA3023222A1 (es)
MX (2) MX2018009090A (es)
TW (2) TW202334427A (es)
WO (1) WO2017131124A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017211461B2 (en) * 2016-01-26 2023-01-12 Nissan Chemical Corporation Single-stranded oligonucleotide
CN110337495B (zh) * 2017-02-06 2024-03-29 日产化学株式会社 单链寡核苷酸
BR112020001430A2 (pt) 2017-07-26 2020-07-28 Nissan Chemical Corporation oligonucleotídeo de fita simples
AU2019237599A1 (en) 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
EP3981431A4 (en) 2019-03-14 2023-06-28 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
JPWO2021153747A1 (es) 2020-01-31 2021-08-05
EP4116419A1 (en) 2020-03-04 2023-01-11 Nissan Chemical Corporation Antisense oligonucleotide of calm2
WO2022211129A1 (ja) * 2021-04-01 2022-10-06 株式会社三和化学研究所 Ａｔｎ１のアンチセンスオリゴヌクレオチド誘導体
KR20240016342A (ko) 2021-05-31 2024-02-06 레나 테라퓨틱스 인크. 리간드-결합 핵산 복합체
EP4428238A1 (en) 2021-11-02 2024-09-11 Rena Therapeutics Inc. Ligand-bound nucleic acid complex

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08154687A (ja) 1994-12-12 1996-06-18 Yamanouchi Pharmaceut Co Ltd アンチセンスオリゴヌクレオチド及び抗ウイルス剤
JPH09110894A (ja) 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JPH11137260A (ja) 1997-11-06 1999-05-25 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス環状ダンベル型ｒｎａ−ｄｎａキメラ化合物及び抗インフルエンザウイルス剤
CA2343067A1 (en) 1998-09-21 2000-03-30 Ribozyme Pharmaceuticals, Inc. Hairpin hybridizer molecules for modulation of gene expression
AU2395900A (en) * 1998-12-31 2000-07-31 Gene Logic, Inc. Assay device comprising mixed probes
JP2003503070A (ja) * 1999-06-25 2003-01-28 インサイト ストラテジー アンド マーケティング リミテッド ヘパラナーゼに対して遠い相同性を有するポリヌクレオチドおよびそれによってコードされるポリペプチド
CA2526831C (en) 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20040014956A1 (en) * 2002-02-01 2004-01-22 Sequitur, Inc. Double-stranded oligonucleotides
WO2003068795A1 (fr) 2002-02-13 2003-08-21 Takeshi Imanishi Analogues de nucleoside et derive d'oligonucleotide comprenant un analogue nucleotidique de ces composes
EP1448590A4 (en) 2002-02-20 2004-12-15 Sirna Therapeutics Inc INHIBITION INDUCED BY THE INTERFERENCE OF RNA OF THE MYC AND MYB GENES OR OF GENES INTERVENING IN THEIR RESPECTIVE PATHWAYS
GB0205455D0 (en) * 2002-03-07 2002-04-24 Molecular Sensing Plc Nucleic acid probes, their synthesis and use
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
AU2003256857A1 (en) 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
WO2004044134A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003299864A1 (en) 2002-12-27 2004-07-29 P. Radhakrishnan Sirna compounds and methods for the downregulation of gene expression
ATE439438T1 (de) * 2003-05-23 2009-08-15 Sirna Therapeutics Inc Durch rna-interferenz vermittelte hemmung der genexpression unter verwendung von chemisch modifizierter sina (short interfering nucleic acid)
EP2371834B1 (en) 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
ZA200706083B (en) * 2005-02-01 2008-09-25 Alcon Inc RNAI-mediated inhibition of ocular targets
CA2658183A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
CN101301478A (zh) * 2007-05-10 2008-11-12 贝勒医学院 以低氧诱导因子1-α(HIF1α)作为靶标的G-四合体寡核苷酸
CA2732229C (en) 2008-07-25 2023-10-17 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
WO2011052436A1 (ja) 2009-10-29 2011-05-05 国立大学法人大阪大学 架橋型人工ヌクレオシドおよびヌクレオチド
ES2809679T3 (es) * 2010-03-08 2021-03-05 Monsanto Technology Llc Moléculas polinucleotídicas para la regulación génica en plantas
DK2558578T3 (en) 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
EP2639307B1 (en) 2010-08-03 2015-03-04 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
JP6129844B2 (ja) * 2011-09-14 2017-05-17 ラナ セラピューティクス インコーポレイテッド 多量体オリゴヌクレオチド化合物
CA2859581C (en) 2011-12-16 2022-03-22 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid
WO2013103146A1 (ja) 2012-01-07 2013-07-11 株式会社ボナック アミノ酸骨格を有する一本鎖核酸分子
WO2014043544A1 (en) * 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
CN103114131B (zh) * 2012-11-30 2018-10-02 珠海市坤元农业科技有限公司 一种引物中部序列干扰pcr技术
CN103333890B (zh) * 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
EP2992098B1 (en) 2013-05-01 2019-03-27 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating hbv and ttr expression
CA2913499A1 (en) 2013-05-30 2014-12-04 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides
CN104419702A (zh) * 2013-09-04 2015-03-18 北京中康万达医药科技有限公司 一种基于生物信息学筛选siRNA的方法
CA2935022A1 (en) 2013-12-27 2015-07-02 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
JP6482475B2 (ja) 2014-01-07 2019-03-13 レナセラピューティクス株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
JP2017505623A (ja) 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物
JPWO2016152352A1 (ja) * 2015-03-20 2018-01-11 国立大学法人名古屋大学 メラノーマ特異的バイオマーカー及びその利用
AU2017211461B2 (en) 2016-01-26 2023-01-12 Nissan Chemical Corporation Single-stranded oligonucleotide
JP2019528312A (ja) * 2016-08-07 2019-10-10 ノバルティス アーゲー ｍＲＮＡ媒介性の免疫化方法
CN110337495B (zh) * 2017-02-06 2024-03-29 日产化学株式会社 单链寡核苷酸
BR112020001430A2 (pt) * 2017-07-26 2020-07-28 Nissan Chemical Corporation oligonucleotídeo de fita simples
AU2019237599A1 (en) * 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
ES2927412T3 (es) * 2018-11-08 2022-11-04 Siemens Healthcare Gmbh Secuenciación directa de nanoporos de ARN con la ayuda de un polinucleótido de horquilla
WO2020154344A1 (en) * 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
EP4116419A1 (en) * 2020-03-04 2023-01-11 Nissan Chemical Corporation Antisense oligonucleotide of calm2

Also Published As

Publication number Publication date
JPWO2017131124A1 (ja) 2018-11-15
JP6988481B2 (ja) 2022-01-05
AU2017211461A1 (en) 2018-09-13
CA3023222A1 (en) 2017-08-03
TW201738376A (zh) 2017-11-01
US20190119683A1 (en) 2019-04-25
BR112018015164A2 (pt) 2018-12-26
WO2017131124A1 (ja) 2017-08-03
AU2017211461B2 (en) 2023-01-12
US11530409B2 (en) 2022-12-20
JP2022050389A (ja) 2022-03-30
MX2018009090A (es) 2019-03-28
TW202334427A (zh) 2023-09-01
JP7435583B2 (ja) 2024-02-21
CN108884462A (zh) 2018-11-23
EP3409779A1 (en) 2018-12-05
JP2024056807A (ja) 2024-04-23
CN116064544A (zh) 2023-05-05
CN108884462B (zh) 2022-11-25
US20230203498A1 (en) 2023-06-29
EP3409779A4 (en) 2019-07-03
TWI803455B (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2023002818A (es) Oligonucleotido de cadena simple.
WO2018041973A9 (en) Chemically modified single-stranded rna-editing oligonucleotides
MX2019009305A (es) Oligonucleotido de cadena simple.
EP4328322A3 (en) Probe library construction
JP2015142558A5 (es)
JP2016526529A5 (es)
JP2017002079A5 (es)
MX2010004984A (es) Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos.
PH12015502273A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2010004452A (es) Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico.
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
MX2016005506A (es) Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.
MX346956B (es) Captura directa, amplificación y secuenciación de objetivo adn usando cebadores inmovilizados.
MX2024006956A (es) Inserciones de adn no virales orientadas.
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
WO2012092569A3 (en) Compositions comprising immunostimulatory nucleic acids and related methods
JP2016528887A5 (es)
NZ630890A (en) Microrna compounds and methods for modulating mir-122
EP4253544A3 (en) Modified messenger rna comprising functional rna elements
MD20170014A2 (ro) Metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
WO2010105815A3 (en) Improved detection of gene expression
MX2024001181A (es) Oligomeros antisentido y metodos de uso de los mismos para el tratamiento de enfermedades asociadas con el gen alfa-glucosidasa acida.
MX2018002998A (es) Derivado de acido nucleico que tiene actividad inmunoestimuladora.
EP3822349A4 (en) DNA POLYMERASE MUTATION SUITABLE FOR NUCLEIC ACID AMPLIFICATION FROM RNA